AGEN
Agenus Inc.
$3.82
+1.87%
2026-05-08
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Key Fundamentals
Forward P/E
-1.64
EPS (TTM)
$0.00
Revenue Growth (YoY)
27.5%
Profit Margin
0.1%
Beta
1.60
Market Cap
$156.6M
Avg Volume (10D)
911K
Recent Breakout Signals
No recent breakout signals detected for AGEN.
Recent Price Range (60 Days)
60D High
$5.08
60D Low
$2.76
Avg Volume
748K
Latest Close
$3.82
Get breakout alerts for AGEN
Sign up for Breakout Scanner to receive daily notifications when AGEN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Agenus Inc. (AGEN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AGEN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AGEN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.